Similar to our observation in ovarian cancer xenograft models, mice bearing PARP inhibitor-resistant TNBC xenografts (Fig. 6c,d) treated with the combination demonstrated reduced tumor growth compared with those treated with either agent alone. This evidence concerns the gene PARP1 and ovarian carcinoma.